QuidelOrtho Reports Preliminary Q1 Revenue Miss, Citing Weak Respiratory Season and China Headwinds
Summary
QuidelOrtho announced preliminary Q1 2026 revenue of $615-$620 million, below expectations due to a weak respiratory season, slower China sales, and delayed EMEA orders, alongside projected negative free cash flow for the quarter.
Key Events
-
Preliminary Q1 Revenue Below Expectations
Reported preliminary unaudited Q1 2026 revenue of $615-$620 million, impacted by a 30% decline in U.S. Influenza-like Illness visits compared to Q1 2025.
-
Multiple Headwinds Cited
Revenue was further affected by slower China distributor sales due to proposed NHSA reimbursement rate reductions and delayed EMEA orders from the Middle East conflict.
-
Negative Q1 Free Cash Flow
The company expects preliminary unaudited free cash flow to be in the range of $(65) to $(70) million for Q1 2026, and negative for the first half of 2026.
-
Full-Year Guidance at Low End
QuidelOrtho believes only the low end of its previously issued full-year 2026 financial guidance remains achievable, indicating a more cautious outlook.
Analysis
This filing provides a challenging preliminary outlook for QuidelOrtho's first quarter, with revenue impacted by multiple external factors including a significantly weaker respiratory season, proposed reimbursement cuts in China, and geopolitical disruptions. The projected negative free cash flow for Q1 and the first half of 2026, following a substantial net loss in fiscal year 2025, highlights ongoing financial pressures. While management is taking cost actions and expects positive full-year free cash flow, the confirmation that only the low end of full-year guidance is achievable suggests a difficult path ahead, especially with the stock trading near 52-week lows. Investors should monitor the full earnings report on May 5 for further details on cost actions and the revised outlook.
At the time of this filing, QDEL was trading at $14.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $13.70 to $38.99. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.